治疗低血容量休克的复苏剂centhaquine  

Resuscitative agent centhaquine in therapy for hypovolemic shock

作　　者：高清[1] 刘建立[2] 王作军[1] GAO Qing;LIU Jian-li;WANG Zuo-jun(Functional Examination Room,the People's Hospital of Linqu,Linqu SHANDONG 262600,China;Department of Cardiology,the Affiliated Hospital of Weifang Medical University,Weifang SHANDONG 262700,China)

机构地区：[1]临朐县人民医院功能检查科,山东临朐262600 [2]潍坊医学院附属医院心内科,山东潍坊262700

出　　处：《中国新药与临床杂志》2021年第6期417-420,共4页Chinese Journal of New Drugs and Clinical Remedies

摘　　要：低血容量休克是严重威胁生命的常见休克类型,主要的病理生理特征是血容量急剧减少,导致组织低灌流和乳酸性酸中毒。Pharmazz公司开发的复苏剂centhaquine于2020年5月在印度获得批准上市,用以辅助标准疗法治疗低血容量休克。centhaquine主要通过与肾上腺素α2B受体相互作用,有效改善心输出量和组织灌流。在临床试验中,centhaquine呈现较好的安全性,与标准疗法联用可显著改善血压、碱缺失、血乳酸水平和致死率等。Hypovolemic shock, the common deadly form of shock, is pathophysiologically characterized by the sharply decreased blood volume which thereby causes the lower tissue perfusion and the lactic acidosis. Centhaquine developed by Pharmazz, Inc. was approved as an adjuvant to the standard of care for the treatment of hypovolemic shock in May 2020 in India. It effectively enhanced the cardiac output and the tissue perfusion through the interaction with adrenergic alpha-2 B receptors. In the clinical trails, centhaquine showed the acceptable safety profile and its combination with the standard of care resulted in the improved the physiological index including blood pressure, base deficit, blood lactate levels, mortality, and so on.

关 键 词：centhaquine 休克 血容量不足 受体 肾上腺素能 

分 类 号：R971[医药卫生—药品]